X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
adult (5) 5
aged (5) 5
female (5) 5
humans (5) 5
male (5) 5
middle aged (5) 5
index medicus (4) 4
oncology (4) 4
aged, 80 and over (3) 3
cancer (3) 3
carcinoma, non-small-cell lung - pathology (3) 3
deoxycytidine - analogs & derivatives (3) 3
lung cancer, non-small cell (3) 3
lung neoplasms - pathology (3) 3
survival (3) 3
therapy (3) 3
treatment outcome (3) 3
analysis (2) 2
antineoplastic combined chemotherapy protocols - therapeutic use (2) 2
asia (2) 2
carcinoma, non-small-cell lung - drug therapy (2) 2
care and treatment (2) 2
chemotherapy (2) 2
cisplatin - administration & dosage (2) 2
deoxycytidine - administration & dosage (2) 2
disease-free survival (2) 2
double-blind method (2) 2
far east - epidemiology (2) 2
hematology, oncology and palliative medicine (2) 2
lung neoplasms - drug therapy (2) 2
medical colleges (2) 2
neoplasm staging (2) 2
non-small cell lung cancer (2) 2
phase-iii trial (2) 2
prevalence (2) 2
retrospective studies (2) 2
tumors (2) 2
1st-line therapy (1) 1
1st-line treatment (1) 1
adenocarcinoma (1) 1
adenocarcinoma - metabolism (1) 1
adenocarcinoma - pathology (1) 1
administration, intravenous (1) 1
administration, oral (1) 1
angiogenesis (1) 1
angiogenesis inhibitors (1) 1
animals (1) 1
antibodies, monoclonal - administration & dosage (1) 1
antibodies, monoclonal, humanized (1) 1
antigen-specific cancer immunotherapy (1) 1
antigens, neoplasm - metabolism (1) 1
antimetabolites, antineoplastic - therapeutic use (1) 1
antimitotic agents (1) 1
antineoplastic agents (1) 1
antineoplastic agents - adverse effects (1) 1
antineoplastic agents - pharmacokinetics (1) 1
antineoplastic agents - therapeutic use (1) 1
antineoplastic combined chemotherapy protocol (1) 1
antineoplastic combined chemotherapy protocols - adverse effects (1) 1
asia, southeastern - epidemiology (1) 1
asian continental ancestry group (1) 1
avail (1) 1
benzimidazoles - adverse effects (1) 1
benzimidazoles - pharmacokinetics (1) 1
benzimidazoles - therapeutic use (1) 1
bevacizumab (1) 1
bile duct neoplasms - drug therapy (1) 1
bile duct neoplasms - pathology (1) 1
bile ducts, intrahepatic (1) 1
biomarkers - blood (1) 1
biomarkers, tumor - analysis (1) 1
biotechnology & applied microbiology (1) 1
cancer research (1) 1
carboplatin - administration & dosage (1) 1
carboplatin-paclitaxel (1) 1
carcinoma, hepatocellular - blood (1) 1
carcinoma, hepatocellular - drug therapy (1) 1
carcinoma, hepatocellular - mortality (1) 1
carcinoma, non-small-cell lung - enzymology (1) 1
carcinoma, non-small-cell lung - genetics (1) 1
carcinoma, non-small-cell lung - metabolism (1) 1
carcinoma, non-small-cell lung - mortality (1) 1
carcinoma, squamous cell - metabolism (1) 1
carcinoma, squamous cell - pathology (1) 1
cell line, tumor (1) 1
chi-square distribution (1) 1
cholangiocarcinoma (1) 1
cholangiocarcinoma - drug therapy (1) 1
cholangiocarcinoma - pathology (1) 1
cisplatin (1) 1
cisplatin - therapeutic use (1) 1
clinical trials (1) 1
complications and side effects (1) 1
confidence intervals (1) 1
deoxycytidine - therapeutic use (1) 1
diagnosis (1) 1
digestive system (1) 1
digestive system diseases (1) 1
disease progression (1) 1
diseases (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 8, pp. 777 - 786
Summary Background The results of FASTACT, a randomised, placebo-controlled, phase 2 study, showed that intercalated chemotherapy and erlotinib significantly... 
Hematology, Oncology and Palliative Medicine | PHASE-III TRIAL | CARBOPLATIN-PACLITAXEL | 1ST-LINE TREATMENT | GEFITINIB | MULTICENTER | THERAPY | NSCLC | ONCOLOGY | ADENOCARCINOMA | OPEN-LABEL | EGFR | Erlotinib Hydrochloride | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Lung Neoplasms - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Lung Neoplasms - pathology | Male | Cisplatin - administration & dosage | Time Factors | DNA Mutational Analysis | Aged, 80 and over | Adult | Female | Quinazolines - administration & dosage | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Genetic Predisposition to Disease | Lung Neoplasms - enzymology | Double-Blind Method | Drug Administration Schedule | Administration, Oral | Carcinoma, Non-Small-Cell Lung - genetics | Deoxycytidine - administration & dosage | Kaplan-Meier Estimate | Proportional Hazards Models | Carboplatin - administration & dosage | Treatment Outcome | Chi-Square Distribution | Carcinoma, Non-Small-Cell Lung - mortality | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Administration, Intravenous | Phenotype | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Asia | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Carcinoma, Non-Small-Cell Lung - enzymology | Mutation | Deoxycytidine - analogs & derivatives | Antimitotic agents | Medical colleges | Care and treatment | Chemotherapy | Clinical trials | Lung cancer, Non-small cell | Antineoplastic agents | Tumors | Cancer | Index Medicus
Journal Article
Lung Cancer, ISSN 0169-5002, 2016, Volume 101, pp. 137 - 144
Journal Article
Hepatology, ISSN 0270-9139, 09/2016, Volume 64, Issue 3, pp. 774 - 784
Journal Article
OncoTargets and Therapy, ISSN 1178-6930, 05/2014, Volume 7, pp. 815 - 821
Objective: The aims of this study were to estimate the prevalence and examine the factors associated with major depressive disorder (MDD) in lung cancer... 
Lung cancer | Major depressive disorder | Prevalence | DIAGNOSIS | SYMPTOM CLUSTER | RISK-FACTORS | FATIGUE | DISTRESS | RELIABILITY | DISTURBANCE | lung cancer | prevalence | major depressive disorder | ONCOLOGY | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | SLEEP QUALITY | QUALITY-OF-LIFE | VALIDITY | Psychological aspects | Complications and side effects | Risk factors | Distribution
Journal Article
Asia‐Pacific Journal of Clinical Oncology, ISSN 1743-7555, 06/2011, Volume 7, Issue 2, pp. 4 - 12
Aim:  The phase III AVAiL study evaluated the efficacy and safety of the anti‐vascular epidermal growth factor agent bevacizumab combined with platinum‐based... 
bevacizumab | antineoplastic combined chemotherapy protocol | Asian continental ancestry group | vascular endothelial growth factor | non‐small cell lung cancer | Antineoplastic combined chemotherapy protocol | Vascular endothelial growth factor | Non-small cell lung cancer | Bevacizumab | non-small cell lung cancer | PHASE-III TRIAL | SURVIVAL | PLACEBO | AVAIL | ONCOLOGY | JAPAN | 1ST-LINE THERAPY | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - drug therapy | Double-Blind Method | Deoxycytidine - administration & dosage | Humans | Middle Aged | Neoplasm Recurrence, Local - drug therapy | Lung Neoplasms - pathology | Male | Cisplatin - administration & dosage | Neoplasm Recurrence, Local - pathology | Antibodies, Monoclonal, Humanized | Disease-Free Survival | Asian Continental Ancestry Group | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Asia | Adult | Female | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Neoplasm Staging | Deoxycytidine - analogs & derivatives | Hypertension | Medical colleges | Relapse | Endothelial growth factors | Oncology, Experimental | Respiratory agents | Research | Lung cancer, Non-small cell | Endothelium | Diseases | Chemotherapy | Epidermal growth factor | Analysis | Angiogenesis inhibitors | Cancer
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.